
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
0.3822 US$
−0.0163 US$ · -4.09%
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
الإغلاق السابق
0.3822 US$
−0.0163 US$ · -4.09%
بعد ساعات التداول
0.38 US$
−0.0022 US$ · -0.58%
9 أكتوبر، 7:29 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
نطاق اليوم
السعر الحالي 0.3822 US$
نطاق 52 أسبوعًا
السعر الحالي 0.3822 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
29
مرتفع السعر
المشاعر
60
مختلط
المخاطر
69
مخاطر مرتفعة
الزخم
20
هبوط قوي
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
نطاق اليوم
السعر الحالي 0.3822 US$
نطاق 52 أسبوعًا
السعر الحالي 0.3822 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 3.85 مليون USD | 5.58 مليون USD | 2.98 مليون USD | 1.68 مليون USD | 930 ألف USD |
| تكلفة البضاعة المباعة | 4.09 مليون USD | 2.38 مليون USD | 1.49 مليون USD | 909 ألف USD | 767 ألف USD |
| الربح الإجمالي | −241 ألف USD | 3.2 مليون USD | 1.49 مليون USD | 766 ألف USD | 163 ألف USD |
| البحث والتطوير | 7.99 مليون USD | 12.51 مليون USD | 16.2 مليون USD | 20.79 مليون USD | 21.13 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 5.76 مليون USD | 8.98 مليون USD | 7.53 مليون USD | 10.42 مليون USD | 9.99 مليون USD |
| نفقات التشغيل | 13.79 مليون USD | 22 مليون USD | 23.72 مليون USD | 27.71 مليون USD | 31.12 مليون USD |
| دخل الفوائد | 2.47 مليون USD | 957 ألف USD | 1.25 مليون USD | 182 ألف USD | 291 ألف USD |
| مصاريف الفوائد | 1.89 مليون USD | 124 ألف USD | 171 ألف USD | 241 ألف USD | 403 ألف USD |
| الاستهلاك والإطفاء | 1.14 مليون USD | 1.38 مليون USD | 1.3 مليون USD | 2.58 مليون USD | 2.23 مليون USD |
| الدخل التشغيلي | −14.03 مليون USD | −18.8 مليون USD | −22.23 مليون USD | −26.94 مليون USD | −30.95 مليون USD |
| صافي الدخل | −8.49 مليون USD | −16.49 مليون USD | −23.88 مليون USD | −26.64 مليون USD | −27.79 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
2.15 US$
ارتفاع محتمل بنسبة 462.53%عينة محدودة من 4 تقييمات
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.